"Promising Results: Biogen's Alzheimer's Drug Slows Cognitive Decline in Early Study"

Biogen's experimental drug, BIIB080, which targets the removal of the toxic protein tau from brain cells, has shown promising results in a small study for Alzheimer's disease. The drug demonstrated favorable trends in cognition and function, offering hope for a drug class that has previously failed to deliver benefits. However, Biogen emphasizes that these findings are exploratory and from a small study.